| Product Name | $:$ Alobresib |
| :--- | :--- |
| Cat. No. | $:$ |
| CAS No. | $: 1637778$ |
| Molecular Formula | $:$ |
| $\mathrm{C}_{26} \mathrm{H}_{23} \mathrm{~N}_{5} \mathrm{O}_{2}$ |  |
| Molecular Weight | $:$ |
| Target | $:$ |
| Sromodomain |  |
| Solubility | $:$ |
|  |  |



## Biological Activity

GS-5829 (GS5829, Alobresib) is a novel potent, selective BET inhibitor.
GS-5829 dose-dependently induced apoptosis of CLL cells, 400 nM GS-5829 reduced the percentage of viable cells from $94.8 \%$ to $64.4 \%$.
In XTT viability/proliferation assay, GS-5829 demonstrated more potency against MEC-1 CLL cells compared to JQ1 with IC50 of 46.4 nM .
GS-5829 inhibited CLL cell proliferation and induced leukemia cell apoptosis through deregulation of key signaling pathways, such as BLK, AKT, ERK1/2, and MYC.
GS-5829 also inhibited NF-кB signaling. GS-5829 significantly reduced c-Myc protein expression in ARK2 xenograft tumor samples, impaired USC-ARK2 xenograft tumor growth in vivo.

## References

Bonazzoli E, et al. Clin Cancer Res. 2018 Oct 1;24(19):4845-4853.
Kim E, et al. Leukemia. 2020 Jun;34(6):1588-1598.

